LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Cytek Biosciences Inc

Open

SectorHealthcare

2.67

Overview

Share price change

24h

Current

Min

2.49

Max

2.66

Key metrics

By Trading Economics

Income

-21M

-11M

Sales

-16M

41M

EPS

-0.027

Profit margin

-27.503

Employees

648

EBITDA

-13M

-15M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+133.7% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-110M

383M

Previous open

2.67

Previous close

2.67

News Sentiment

By Acuity

50%

50%

173 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Cytek Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 maj 2025, 22:52 UTC

Earnings
Major Market Movers

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 maj 2025, 20:37 UTC

Top News
Earnings

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 maj 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 maj 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 maj 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 maj 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 maj 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 maj 2025, 22:46 UTC

Top News
Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 maj 2025, 21:58 UTC

Earnings

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 maj 2025, 21:24 UTC

Earnings

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 maj 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 maj 2025, 20:54 UTC

Market Talk
Earnings

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 maj 2025, 20:54 UTC

Earnings

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 maj 2025, 20:51 UTC

Earnings

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 maj 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 maj 2025, 20:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 maj 2025, 20:50 UTC

Earnings

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 maj 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 maj 2025, 20:25 UTC

Earnings

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer Comparison

Price change

Cytek Biosciences Inc Forecast

Price Target

By TipRanks

133.7% upside

12 Months Forecast

Average 6.38 USD  133.7%

High 9 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forCytek Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

1

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

3.7 / 3.8Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

173 / 382 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.